About the Company

Founded on Breakthrough mRNA Research

BEMY is a science-driven and technology-empowered cosmeceuticals company headquartered in Houston, Texas. The company, founded by PhD-level scientists and entrepreneurs with significant expertise in the design and application of cosmetic and pharmaceutical products, specializes in small molecules and messenger RNA (mRNA), as well as proprietary cosmetic base formulations. Enabled by patented technology, our scientists have engineered a new and highly innovative platform in skin rejuvenation.

What this video shows us is that cells can be transfected with much higher efficiency using mRNA. BEMY is able to grow and treat the customer’s cells safely in a lab at a much greater ability than relying on DNA-based cell transfection.

Data-Driven Analysis

Skin Cells (fibroblasts) manufacture the proteins tasked with keeping the skin looking young. BEMY has the ability to optimize the quality and concentration of these proteins by using our patented mRNA technology to ramp up protein production. What’s more, the specific types of proteins targeted can be individualized based on specific needs of that customer’s own skin.

Meet Our Team

By way of serendipitous events, the idea of combining proven RNA technology with personalized skin cream became a formal business venture in 2016. BEMY sought to become the first and only company in the world to use RNA reprogramming technologies for rejuvenating adult human skin cells and to use youthful growth factors from these cells for skin care. Through harmonious expertise in business and science, the founders jumped on the opportunity to address an important and unmet gap in the cosmetics industry.

Ted SchwarzChief Executive Officer

25 years executive leadership experience in pharmaceuticals, medical aesthetics, medical device and consumer products.

Eduard Yakubov, Ph.D.Chief Scientific Officer

16+ years in the field of RNA Pharmacobiology. First to demonstrate that somatic cells can be reprogrammed (using mRNA) into induced pluripotent stem (iPS) cells and use modified mRNA (mmRNA) encoding telomerase reverse transcriptase (TERT) to extend telomeres in human cells. Ph.D., Weizmann Institute of Science, Israel. Stanford University.

Andrew Frankel, M.D.Chief Medical Officer

Dr. Andrew Frankel is a world-renowned facial plasticsurgeon specializing in facial rejuvenation procedures. While maintaining a busy surgical practice at the Lasky Clinic in Beverly Hills, CA, Dr. Frankel also remains active in clinical research. He has participated in FDA trials involving the use of hyaluronic acid fillers for facial rejuvenation and has authored numerous publications and book chapters. A past clinical professor at both the University of Southern California Keck School of Medicine as well as University of California, Los Angeles, Dr. Frankel still actively lectures nationally and internationally on topics related to aging. He also continues to serve as a Fellowship Director for the American Academy of Facial Plastic and Reconstructive Surgery.

Brad Pylant

CO-Founder and CEO of phaRNA. PhaRNA provides high-quality messenger RNA to the scientific and medical communities and was recently named one of the top 10 synthetic biology companies by Life Science Review. Brad has been President of Village Compounding Pharmacy for 14 years, which has been named one of top 2 U.S. compounding pharmacies in the industry. VCP specializes in customizing formulations for precision medicine. BBA, Texas A&M, MBA, TCU.

Ludmila Iakubova, M.D.Lab Specialist

Originally from Muldova, Dr. Iakubova brings many years of experience in working with cell cultures and more specifically fibroblast propagation. She is also an expert in protein isolation of fibroblast skin cells.

Mark JohnsonVP of Business Development

Founder, Amerra, Inc. Mark has helped hundreds of life science companies promote technologies through medical visualization since 2001. Texas A&M University.

Advisors

BEMY is fortunate to have key advisors lend their expertise to help improve performance and make necessary changes to achieve success.

John Ramunas, Ph.D.Scientist

Expert in stem cell biology using modified mRNA encoding human Telomerase Reverse Transcriptase to extend telomeres in human cells. Postdoctoral, Stanford University. Postdoctoral Scholar, Baxter Laboratory for Stem Cell Research, Stanford University. Founder & CEO, Rejuvenation Technologies.

Mark Rubin, M.D.Dermatologist

Mark G. Rubin, M.D. is a board-certified dermatologist. He currently practices at The Lasky Skin Center in Beverly Hills. His practice is limited exclusively to cosmetic dermatology. In addition, Dr. Rubin is an emeritus assistant clinical professor of dermatology at The University of California, San Diego and an associate professor of dermatology at Vanderbilt University in Nashville. Dr. Rubin is a specialist in skin resurfacing and has written multiple papers, book chapters and two textbooks on skin rejuvenation. He has personally trained over 600 physicians in his technique of skin rejuvenation.

Ava Shamban, MDCelebrity Dermatologist

Dr. Shamban is an American celebrity dermatologist who has made numerous appearances on television and cosmetic publications as an authority on the subject. She is currently a board-certified dermatologist based in Los Angeles, and founder of Ava MD.

Jeff Harder, J.D.Advisor

Jeff Harder has been at the center of venture capital and angel investor transactions in a wide variety of industries. Jeff’s representation of a leading life science industry venture capital firms over the past 30 years has positioned him at the forefront of the technology industry, serving clients from Massachusetts to Texas, Florida to California.

Michael LoweBusiness Executive

CEO, Noleus Technologies. He previously served as the CEO of Houston-based medical device company, OrthoAccel® Technologies, Inc., a position that he held for nearly ten years, from its founding through the end of 2016. OrthoAccel was named to the Deloitte FAST 500 list of fastest growing technology companies in North America for two consecutive years

Science-Driven

The company, founded by PhD scientists and entrepreneurs uses modulating components, such as messenger RNA (mRNA), in rejuvenating and optimizing the cellular components, and combining these autologous and youthful proteins, peptides, cytokines, growth factors with other ingredients, for cosmetic and therapeutic applications.

Discovery

BEMY is creating a paradigm shift in the cosmetic industry. We’ve discovered how to customize our formulations to address an individual’s specific needs as it pertains to the skin. We are only scratching the surface of our technology’s full potential, and are poised to continually enhance our skin rejuvenation product as well as to apply our science for other types of cosmetic applications.

Ultra-Personalization and Beyond

BEMY is building upon a platform technology can be applied to many other uses. By establishing ourselves as a leader in ultra-personalized cosmetic products, the company will be offering semi-personalized products for mass market distribution.

DATA-DRIVEN SOLUTIONS

Formulating with AI

By giving customers the ability to provide feedback and customize their products online, our system will keep track of trends, thus constantly optimizing small molecule and base formulations. In essence, BEMY’s products are always improving in real-time. This information will be used to help create the first roll out of semi-personalized products for mass market distribution.

A Skin Care Revolution

BEMY is the first company in the world harnessing patented mRNA technology for production of a cosmetic skin care line.